Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Shares Shorted: Short Interest Down 53.4% in September

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) was the target of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 9,250 shares, a decline of 53.4% from the September 15th total of 19,861 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 6,232 shares, the days-to-cover ratio is currently 1.5 days.

Ascentage Pharma Group International Trading Up 2.8%

Shares of NASDAQ:AAPG traded up $0.41 during trading on Tuesday, reaching $15.16. 1,235 shares of the company traded hands, compared to its average volume of 6,820. The firm has a fifty day simple moving average of $16.68 and a 200 day simple moving average of $19.27. Ascentage Pharma Group International has a 1-year low of $14.45 and a 1-year high of $37.50. The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09.

Get Ascentage Pharma Group International alerts:

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last issued its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million during the quarter. Analysts predict that Ascentage Pharma Group International will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

AAPG has been the topic of a number of recent analyst reports. Citizens Jmp assumed coverage on Ascentage Pharma Group International in a research report on Tuesday. They set a “market outperform” rating and a $35.00 target price on the stock. Citigroup assumed coverage on Ascentage Pharma Group International in a research report on Tuesday. They issued an “outperform” rating for the company. JPMorgan Chase & Co. dropped their price target on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday, October 8th. Finally, BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $43.67.

View Our Latest Stock Report on AAPG

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.

See Also

• Five stocks we like better than Ascentage Pharma Group International
• Flex’s AI Infrastructure Spin-Off Could Unlock Hidden Value
• A Silent Winner: Texas Instruments Anchors the AI Supercycle
• Amazon’s $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?
• Enlisting Capital: Wolfspeed’s Defense Deal

Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.